Logo do repositório
 
Publicação

Inflammatory Bowel Disease patients’ perspectives during COVID-19 pandemic: results from a Portuguese survey

2021Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorRevés, Joana Branco
dc.contributor.authorFrias-Gomes, Catarina
dc.contributor.authorMorão, Bárbara
dc.contributor.authorNascimento, Catarina
dc.contributor.authorPalmela, Carolina
dc.contributor.authorFidalgo, Catarina
dc.contributor.authorRoque Ramos, Lídia
dc.contributor.authorSampaio, Ana
dc.contributor.authorGlória, Luísa
dc.contributor.authorCravo, Marília
dc.contributor.authorTorres, Joana
dc.date.accessioned2022-06-01T16:03:55Z
dc.date.available2022-06-01T16:03:55Z
dc.date.issued2021
dc.description© 2021 Sociedade Portuguesa de Gastrenterologia. Published by S. Karger AG, BaselThis is an Open Access article licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense), applicable to the online version of the article only. Usage and distribution for com- mercial purposes requires written permissionpt_PT
dc.description.abstractIntroduction: Patients with inflammatory bowel disease (IBD) do not seem to be at increased risk of infection by SARS-CoV-2, but there is a concern whether immunosuppressive therapy may be associated with more severe disease. Several clinical practice recommendations have been published to help guide IBD care during the COVID-19 pandemic. Nonetheless, few studies have addressed patients' perspectives and fears. We aimed to evaluate Portuguese IBD patients' perspectives on the clinical management of their disease during the SARS-CoV-2 pandemic as well as the impact on their professional life. Methods: An anonymous electronic survey was created using REDCap and was distributed by the Portuguese Association of Inflammatory Bowel Disease (APDI) between May and August 2020. Patients' perspectives on immunosuppressive therapy, disease management, interaction with gastroenterology departments, and the impact of the pandemic in their professional life were assessed. Patients' proposals to improve medical care were also evaluated. Descriptive analysis and logistic regression were performed. Results: A total of 137 participants answered the survey (79.6% females, mean age 41.7 ± 12.1 years). Although having IBD and receiving treatment with immunosuppressors (thiopurines, steroids, or biologics) were considered promotors of anxiety, most patients (85.4%) agreed that disease remission was a priority and only a minority of patients interrupted their treatment during the pandemic. In multivariate analysis, active disease, biologic treatment, and use of corticosteroids in the last 3 months were perceived by the patients as high-risk features for increased risk of SARS-Cov-2 infection and more severe disease. Fifty-nine patients (44%) believed that their follow-up was influenced by the pandemic and only 58.8% felt that they had the opportunity to discuss their therapeutic options with their doctor. Sixty-three patients (46.0%) were working from home during the pandemic, although this decision was related to IBD and immunosuppressive therapy in only 36.5 and 39.7% of the cases, respectively. Areas where care could have been improved during the pandemic were identified by patients, namely enhancement of the communication with IBD professionals, conciliation of telemedicine with face-to-face appointments, and facilitation of the interaction between patients and employers. Conclusion: Most patients agreed that maintaining IBD remission is crucial, and only a minority of the patients stopped their treatment as per their own initiative. IBD status only had a small influence on patients' professional activity during the COVID-19 outbreak, with most changes being related to the pandemic itself.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationGE Port J Gastroenterol. 2021 Sep 16;5:1-9pt_PT
dc.identifier.doi10.1159/000518945pt_PT
dc.identifier.eissn2387-1954
dc.identifier.issn2341-4545
dc.identifier.urihttp://hdl.handle.net/10451/53260
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherKargerpt_PT
dc.relation.publisherversionhttps://www.karger.com/Journal/Home/272027pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt_PT
dc.subjectCOVID-19pt_PT
dc.subjectCrohn's diseasept_PT
dc.subjectInflammatory bowel diseasept_PT
dc.subjectUlcerative colitispt_PT
dc.titleInflammatory Bowel Disease patients’ perspectives during COVID-19 pandemic: results from a Portuguese surveypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage9pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleGE - Portuguese Journal of Gastroenterologypt_PT
person.familyNameCravo
person.familyNameTorres
person.givenNameMarília
person.givenNameJoana
person.identifier.orcid0000-0001-8309-4599
person.identifier.orcid0000-0003-2895-5821
person.identifier.scopus-author-id35551480200
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication01f30332-6fe1-4d53-9f07-905ec4697d78
relation.isAuthorOfPublication38a18ac5-f4d2-4748-adf8-d41eefac84ab
relation.isAuthorOfPublication.latestForDiscovery38a18ac5-f4d2-4748-adf8-d41eefac84ab

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Bowel_disease.pdf
Tamanho:
228.11 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

FM - Artigos em Revistas Nacionais